Osteopathic treatment of patients suffering from chronic non-specific low back pain: A dose- response study. Dr. Espen Glomsrød Osteopath DO MSc, University.

Slides:

Advertisements

Similar presentations

Understanding Obesity through Sociology

Advertisements

Rate Rhythm P-R Interval QRS Duration P-QRS Ratio Treatment Causes.

How to reach & maintain a healthy weight! Dr Tracy Jackson Dr Gail Bohin - Clinical Psychologist Zara Catlow - Dietician Patient Participation Group.

Figure 1. Higher prevalence of significant GER symptoms in patients with COPD. The prevalence of significant GER symptoms (heartburn and/or regurgitation.

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-1 Phase 3 Treatment Naïve Source: Afdhal N, et al. N.

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2 Phase 3 Treatment Experienced Source: Afdhal N, et.

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir for 8 or 12 weeks in HCV GT1 ION-3 Phase 3 Treatment Naïve Kowdley K, et al. N Engl J Med.

Hepatitis web study Hepatitis web study Sofosbuvir + Ribavirin to Prevent Post-Transplant HCV Recurrence Phase 2 Curry MP, et al. Gastroenterology. 2015;148:100-7.

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia.

Hepatitis web study Hepatitis web study Sofosbuvir + Ribavirin in HCV Recurrence Following Liver Transplantation Phase 2 Charlton M, et al. Gastroenterology.

analysis from the SHIFT study

Effectiveness of Orthoses and Foot Training in patients with Patellofemoral Pain and hyperpronation Mølgaard C. (1+2), Kaalund S.(3), Christensen M.(1),

Pramlintide Advisory Committee July 26, 2001 Symlin ® Amylin Pharmaceuticals New Drug Application (21-332) Advisory Committee Meeting Bethesda, Maryland.

Hepatitis web study Hepatitis web study Sofosbuvir + Ribavirin in HCV GT 4 Egyptian Ancestry Trial Phase 2 Ruane PJ, et al. J Hepatol. 2015;62:

OVBIAGELE B, DIENER H-C, YUSUF S, ET AL., PROFESS INVESTIGATORS. LEVEL OF SYSTOLIC BLOOD PRESSURE WITHIN THE NORMAL RANGE AND RISK OF RECURRENT STROKE.

به نام ايزد يکتا Clinical Trial Design Dr. Khalili 1  The common types  Advantages and limitations  Usual applications.

Journal Club 埼玉医科大学総合医療センター内分泌・糖尿病内科 Department of Endocrinology and Diabetes, Saitama Medical Center, Saitama Medical University 松田昌文 Matsuda, Masafumi.

ATOMIC  Design  Objective –SVR 24 by ITT-analysis, detection of a 30% or 25% difference between two treatment groups, 2-sided significance level of 5%,

Ardiana Murtezani MD, PhD 1, 2, Nerimane Abazi MD 1,2, Zana Ibraimi PHARM PhD 2,Fatime Haxholli MD 1,2, Zana Agani DDS PhD 2,3, Elena Kamberi DDS 2.

A Randomized Placebo- Controlled Trial of Metformin for the Treatment of HIV Lipodystrophy Rakhi Kohli MD MS, Christine Wanke MD, Sherwood Gorbach MD,

ELECTRON  Design SOF + RBV Randomisation* 1 : 1 : 1 : 1 Open-label ELECTRON Study: SOF-based therapy for genotypes 1, 2 and 3 W8W4W12 ≥ 19 years Chronic.

Immediate effect of transcutaneous Electrical Nerve Stimulation on Pain and flexibility in chronic nonspecific low back pain: A pilot study Authors: N.

 BSA (m 2 ) = √ Ht(in) X wt (lb) 3131 Ht (cm) X wt (kg) 3600 Mosteller,RD " Simplified Calculation of Body Surface Area", N Engl J Med 1987, 317 (17):

Clinical Trial Results. org Anti-Inflammatory Effects of Pioglitazone and/or Simvastatin in High Cardiovascular Risk Patients With Elevated High Sensitivity.

Symptom Distress During Breast Cancer Chemotherapy Does Race Matter? Margaret Quinn Rosenzweig, PhD, FNP-BC,AOCNP Associate Professor University of Pittsburgh.

W24 ≥ 18 years Chronic HCV infection Genotype 1 Treatment naïve Early fibrosis to compensated cirrhosis No HBV or HIV co-infection N = 10 SOF + weight-based.

Pharmacokinetics of Vancomycin in Adult Oncology Patients Hadeel Al-Kofide MS.c; Iman Zaghloul PhD; and Lamya Al-Naim PharmD Department of Clinical Pharmacy,

Hepatitis web study Hepatitis web study Sofosbuvir + Ribavirin to Prevent Post-Transplant HCV Recurrence Phase 2 Curry MP, et al. Gastroenterology. 2014;September.

Placebo + PR W24 DCV + PR Placebo + PR Yes Dore GJ. Gastroenterology 2015;148: COMMAND GT2/3 COMMAND GT2/3 Study: daclatasvir + PEG-IFN + RBV for.

The effect of numbers and duration between osteopathic treatments on Patients suffering from foot related pain; a dose-response study Joachim Kaufmann.

Trends in Treatment of Recurrent Hepatitis C After Liver Transplantation Kate Forgan-Smith KA Stuart 1,4, C Tallis 1,4 GA Macdonald 1,3,4, J Fawcett 2,3.

Determining Preferences for Symptom Management Assistance For Those with Oral Anti-Cancer Treatment Sandra L. Spoelstra, PhD, RN GSA Annual Meeting New.

KT AS A QUALITY INDICATOR OF HAEMODIALYSIS ADEQUACY: COMPARISON OF KT/V, KT ACCORDING TO THE GENDER AND BODY SURFACE AREA The dialysis dose monitored with.

POCT FOR DIAGNOSIS OF CELIAC DISEASE IN EGYPTIAN CHILDREN Prof Dr Mona Ahmed Abu Zekry Professor of Pediatrics and Pediatric Gastroenterology Children.

1 Dose-Response of Spinal Manipulation for Cervicogenic Headache: Long-Term Outcomes from a Randomized Trial Mitchell Haas, DC, MA 1 Adele Spegman, PhD,

Risk Factors for Lower Extremity Ulcer in the Morbidly Obese Diabetics Elly Budiman-Mak MD, MPH, MS. 1,2 Min–Woong Sohn, Ph.D. 1,3 Rodney M. Stuck, DPM.

Comparison of Inhaled Antibiotics for the Treatment of Chronic Pseudomonas aeruginosa Lung Infection in Patients With Cystic Fibrosis: Systematic Literature.

Copyright © 2003 American Medical Association. All rights reserved.

Key publication slides

Fibromyalgia Impact Questionnaire McGill Pain Questionnaire

Comparison between the Effect of Six Weeks Morning or Evening Aerobic Exercise on Appetite and Anthropometric Indices Zahra Alizadeh, MD Assistant Professor.

Copyright © 2015 by the American Osteopathic Association.

Key publication slides

Copyright © 2015 by the American Osteopathic Association.

• the prevalence of pain related fear in patients with chronic

Copyright © 2015 by the American Osteopathic Association.

Jonathan W. Decker, MSN, ARNP, PhD-c Karen E. Dennis, PhD, RN, FAAN

during propofol and remifentanil induction

Dominique Hansen, PhD, FESC

BHS Methods in Behavioral Sciences I

The Impact of Pain Management on Quality of Life

Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2

ION-3 Study: LDV/SOF + RBV for naïve genotype 1

Ledipasvir-Sofosbuvir +/- Ribavirin for 8 or 12 weeks in HCV GT1 ION-3

Proportion of Patients Achieving a ≥30% Reduction in Pain Scores at Week 12 of Stable Dose Treatment

ARNO TRIAL (Antithrombotic Regimens aNd Outcome)

Weighted Interval Scheduling

Volume 12, Issue 9, Pages (September 2013)

Supplemental Figure 1A Pt Pt Pre-treatment

A double-blind randomized controlled trial comparing alternate forms of high molecular weight hyaluronan for the treatment of osteoarthritis of the knee

Weighted Interval Scheduling

Prolonged Treatment with Transdermal Fentanyl in Neuropathic Pain

Challenges with heparin-based anticoagulation during cardiopulmonary bypass in children: Impact of low antithrombin activity Cedric Manlhiot, PhD, Colleen.

Comparison between groups

Phase 2 Treatment Experienced (with Sofosbuvir and Ribavirin)

Safety and Efficacy of the Fixed-Dose Combination Regimen of MK-3682 / Grazoprevir / MK-8408 (Ruzasvir) in Cirrhotic or Non-cirrhotic Patients with Chronic.

Ustekinumab treatment is associated with decreased systemic and vascular inflammation in patients with moderate-to-severe psoriasis: Feasibility study.

Physical Function in Patients with Cancer

Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: A pooled analysis of the Phase 3 VOYAGE 1 and VOYAGE.

Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase.

Presentation transcript:

Osteopathic treatment of patients suffering from chronic non-specific low back pain: A dose- response study. Dr. Espen Glomsrød Osteopath DO MSc, University of Bergen, Norway Prof. Stig Larsen Dr.Sc, professor CCRM University of Life Sciences Norway Ass Prof. Roar Jensen Phd MT, University of Bergen Norway

Aim To determine the combination of treatment numbers and intervals obtaining optimal effect of osteopathic treatment in patients with chronic non-specific low back pain. To determine the combination of treatment numbers and intervals obtaining optimal effect of osteopathic treatment in patients with chronic non-specific low back pain.

Study Design [ Study Design [ 2 2 factorial design ] Number of treatments Treatment interval (days)

Study Design [ Study Design [ 2 2 factorial design ] n 1 = 3 14 days interval n 2 = 3 7 days interval n 1 = 3 14 days interval n 2 = 3 7 days interval N = 6 patients were given 2 treatments N = 6 patients were given 4 treatments N= 12 Patients with chronic unspecific low back pain

Material Description FactorNumber of treatmentsTreatment intervals Total material 2 treatment4 treatment7 Days14 Days Age (Years) 44,3 (15,3)47,2 (12,1)46,8 (10.8)44,7 (16,3)45,8 (13,3) Weight (Kg) 80,3 (6,9)74,8 (9,6)76,5 (9,3)78,7 (8,4)77,6 (8,5) Height (cm) 172 (7,7)173 (4,9)170 (5,4)176 (5,6)173 (6,1) BMI Kg/m 2 27,1 (1,1)25,0 (3,1)26,6 (3,0)25,4 (1,9)26,0 ( 2,5) 26,0 – ,5 – 30,122,8 – 30,122,5 – 27,522,5 – 30,1

Baseline Oswestry score within treatment groups Treatment groups Mean 95% Confidence interval Number of treatments 2 Treatments 35,8 16,6 – 55,0 28,3 12,3 – 44,4 4 Treatments Duration between treatments (days) 7 days 34,8 17,8 – 51,8 29,3 10,5 – 48,2 14 days Two treatments /14 days interval38,7 0 – 95,8 Two treatments / 7 days interval32,9 0 – 74,8 Four treatments / 14 days interval20,0 10,1 – 29,9 Four treatments / 7 days interval36,7 0 – 83,9

Results Results Comparison of reduction in Oswestry score from baseline to two weeks post treatment Treatment groupsWithin groupsBetween groups Number of treatments 2 Treatments4,9 [- 8,2 – 17.9] 7,5[- 14,6 – 29,6] 4 Treatments12,3[ - 9,5 – 34,2] Duration between treatments (days) 7 days13,9 [-6.9 –34,6] 10,5[- 11,0 – 32,0] 14 days3,3 [- 10,2 – 16,8] Total8,6[-2,1 – 19,3]

Reductions in Oswestry scores from baseline to two weeks post treatment in the combined groups. Within each pair of groups, one given two treatments (yellow bars) and one given four treatments (blue bars).

Conclusion The effect was found to increase with increasing number of treatments and a reduced treatment interval. Four treatments with intervals of 7 days were found to be the superior of the four chosen regimens. An interaction in effect between the number of treatments and the duration of the treatment interval was detected.